National - Economist

**National - Economist**

**Background**

Antimicrobial resistance (AMR) is an emerging global public health concern that puts the gains of the Millennium Development Goals at risk and endangers efforts to achieve the 2030 Sustainable Development Goals (SDG). To address the global AMR issue, WHO developed a Global Action Plan on AMR (AMR GAP), which has been endorsed by the World Health Assembly WHA68.7 in 2015.

The Fleming Fund was established by the UK Government in response to the UK AMR Review published in 2016. It is a UK aid programme supporting up to 25 countries across Africa and Asia to tackle AMR. The Fund is managed by the Department of Health and Social Care (DHSC) and invests in strengthening surveillance systems through a portfolio of country and regional grants, strategic alignment grants, and fellowship schemes. Mott MacDonald is the commercially appointed Management Agent for the Fleming Fund Country and Regional Grants.

The Fleming Fund Country Grant in Indonesia (FFCGI) has been implemented by a DAI-led consortium since January 2020. The second phase of Indonesia Country Grant is being implemented over a period of up to 22 months from March 2024 to December 2025. It will build on the work of Phase I and will focus on improving the quantity, quality and use of AMR, AMU, and AMC surveillance data, from a wider range of sources and sectors, with additional capture, analysis and use of socio-economic data, and improving the sustainability of Fleming Fund investments.

**Recruitment**

Individuals and institutions will be considered to fulfil this role(s). Given the specialised nature of the assignment, the One Health economic and financial analysis role may be recruited for/offered to an institution or individual(s).

Interested individuals/institutions may submit CV(s) and proposed daily rate(s).

**Qualifications and experience**

**Scope of Work**

The Economist(s) will support the implementation of a One Health economic and financial analysis and Burden of Disease study. The scope of work is described below.
- One Health economic and financial analysis _
- The specialist/institution will conduct a one health economic and financial analysis of the project. The specialist/institution will work under the technical supervision of the international one health economist and report to the project team leader. The specialist/institution will prepare a report on economic and financial analysis including a linked document with a spreadsheet of collected data.

Specifically, the specialist/institution will do the following:

- Develop and administer data collection tools to assemble farm data (productivity, antimicrobial use and costs, etc.), health service data (antimicrobial consumption, surveillance and diagnostic costs, treatment lengths and costs, AMR associated attributed and associated mortality and morbidity) and relevant macroeconomic data in a referenced data base.
- Estimate the financial impact of AMR and AMR control interventions for farm productivity, and cost-benefit or cost-effectiveness indicators using a partial budgeting approach.
- Estimate the financial impact of AMR and AMR control interventions for health service providers and the Government of Indonesia.
- Identify financial incentives for responsible antimicrobial use and consumption.
- Estimate the economic impact of AMR for the national economy.
- Participate in the work planning sessions for economic assessment scoping activity with relevant Grant technical team members.
- Review global, Indonesian and project data bases or electronic information systems and identify available data sets and data use mechanisms for the once health economic assessment of AMR.
- Consult with the Team Lead, Grant technical leads, including other experts (e.g. International Public Health Expert) at key stages during development of the proposed study design and seek feedback from counterparts where possible, given the limited timeframe.
- Discuss with the Management Agent on the economic assessment activity if requested by the Team Lead.
- Submit draft one health economic assessment report by 15 March 2025 to the Grant Team Lead.
- Support hosting of dissemination workshop by
- Provide support to the burden of disease study which will be progressing in parallel_

To complement the economic assessment being conducted in parallel, the specialist/institution will assist in the implementation of a planned study to estimate the burden of disease associated with AMR (BoD-AMR). ‘Burden of disease’ is a measure that combines the impact of living with illness and injury, and dying prematurely. Burden of disease is comprised of two key measures: years of life lost (YLL) to measure premature deaths relative to life expectancy, and years lived with disability (YLD), to measure the impact of living in poor health for the remainder of the life span. These measures are combined as a single measure, “disability-adjusted life years”, or DALYs. When expressed